in varying degrees.levofloxacinMonitor Closely (1)prochlorperazine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levoketoconazoleSerious - Use Alternative (1)prochlorperazine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.levorphanolMonitor Closely (1)levorphanol and prochlorperazine both increase sedation. Use Caution/Monitor.liraglutideMonitor Closely (1)prochlorperazine, liraglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.lisdexamfetamineMonitor Closely (2)prochlorperazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.lisinoprilMinor (1)prochlorperazine increases effects of lisinopril by unspecified interaction mechanism. Minor/Significance Unknown.lisurideSerious - Use Alternative (1)prochlorperazine decreases effects of lisuride by pharmacodynamic antagonism. Contraindicated.lithiumMonitor Closely (2)lithium, prochlorperazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved. lithium and prochlorperazine both decrease QTc interval. Use Caution/Monitor.lofepramineMonitor Closely (1)prochlorperazine and lofepramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)lofepramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. lofepramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.lofexidineMonitor Closely (1)prochlorperazine and lofexidine both increase sedation. Use Caution/Monitor.loprazolamMonitor Closely (1)loprazolam and prochlorperazine both increase sedation. Use Caution/Monitor.lorazepamMonitor Closely (1)lorazepam and prochlorperazine both increase sedation. Use Caution/Monitor.lormetazepamMonitor Closely (1)lormetazepam and prochlorperazine both increase sedation. Use Caution/Monitor.loxapineMonitor Closely (2)loxapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. loxapine and prochlorperazine both increase sedation. Use Caution/Monitor.loxapine inhaledMonitor Closely (2)loxapine inhaled and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. loxapine inhaled and prochlorperazine both increase sedation. Use Caution/Monitor.lumefantrineMonitor Closely (1)lumefantrine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)prochlorperazine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.lurasidoneMonitor Closely (1)lurasidone, prochlorperazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilineMonitor Closely (2)prochlorperazine and maprotiline both increase QTc interval. Use Caution/Monitor. prochlorperazine and maprotiline both increase sedation. Use Caution/Monitor.Minor (2)maprotiline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. maprotiline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.maravirocMinor (1)maraviroc will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.marijuanaMonitor Closely (1)prochlorperazine and marijuana both increase sedation. Use Caution/Monitor.Minor (1)marijuana will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.meclizineMonitor Closely (3)meclizine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. meclizine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of meclizine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.melatoninMonitor Closely (1)prochlorperazine and melatonin both increase sedation. Use Caution/Monitor.meperidineMonitor Closely (1)meperidine and prochlorperazine both increase sedation. Use Caution/Monitor.meprobamateMonitor Closely (1)prochlorperazine and meprobamate both increase sedation. Use Caution/Monitor.metaproterenolMonitor Closely (1)prochlorperazine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.metaxaloneMonitor Closely (1)metaxalone and prochlorperazine both increase sedation. Use Caution/Monitor.metforminMonitor Closely (1)prochlorperazine decreases effects of metformin by pharmacodynamic antagonism. Use Caution/Monitor. Patient should be closely observed for loss of blood glucose control; when drugs are withdrawn from a patient receiving metformin, patient should be observed closely for hypoglycemia.methadoneMonitor Closely (2)prochlorperazine and methadone both increase QTc interval. Modify Therapy/Monitor Closely. methadone and prochlorperazine both increase sedation. Use Caution/Monitor.methamphetamineMonitor Closely (2)prochlorperazine, methamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methocarbamolMonitor Closely (1)methocarbamol and prochlorperazine both increase sedation. Use Caution/Monitor.methoxsalenMonitor Closely (1)methoxsalen, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive photosensitizing effects.methscopolamineMonitor Closely (3)methscopolamine decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. methscopolamine decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of methscopolamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.methyl aminolevulinateSerious - Use Alternative (1)prochlorperazine, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.methyldopaSerious - Use Alternative (1)prochlorperazine decreases effects of methyldopa by pharmacodynamic antagonism. Contraindicated.methylenedioxymethamphetamineMonitor Closely (2)prochlorperazine, methylenedioxymethamphetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.methylphenidateMonitor Closely (1)prochlorperazine, methylphenidate. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.metoclopramideMonitor Closely (1)prochlorperazine and metoclopramide both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.metoclopramide intranasalSerious - Use Alternative (2)prochlorperazine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient. prochlorperazine increases toxicity of metoclopramide intranasal by pharmacodynamic synergism. Avoid or Use Alternate Drug. Potential for additive effects, including increased frequency and severity of tardive dyskinesia, other extrapyramidal symptoms, and neuroleptic malignant syndrome.metrizamideContraindicated (1)prochlorperazine, metrizamide. Mechanism: unknown. Contraindicated. Risk of seizure. D/C phenothiazine 24h before admin. of metrizamide.metyraponeMinor (1)prochlorperazine decreases effects of metyrapone by unspecified interaction mechanism. Minor/Significance Unknown.metyrosineMinor (1)metyrosine increases toxicity of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased extrapyramidal symptoms.midazolamMonitor Closely (1)midazolam and prochlorperazine both increase sedation. Use Caution/Monitor.midazolam intranasalMonitor Closely (1)midazolam intranasal, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.midodrineMonitor Closely (2)prochlorperazine, midodrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.mirtazapineMonitor Closely (2)mirtazapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. prochlorperazine and mirtazapine both increase sedation. Use Caution/Monitor.modafinilMonitor Closely (1)prochlorperazine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.moexiprilMinor (1)prochlorperazine increases effects of moexipril by unspecified interaction mechanism. Minor/Significance Unknown.morphineMonitor Closely (1)morphine and prochlorperazine both increase sedation. Use Caution/Monitor.motherwortMonitor Closely (1)prochlorperazine and motherwort both increase sedation. Use Caution/Monitor.moxifloxacinSerious - Use Alternative (1)prochlorperazine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.moxonidineMonitor Closely (1)prochlorperazine and moxonidine both increase sedation. Use Caution/Monitor.nabiloneMonitor Closely (1)prochlorperazine and nabilone both increase sedation. Use Caution/Monitor.nalbuphineMonitor Closely (1)nalbuphine and prochlorperazine both increase sedation. Use Caution/Monitor.nilotinibSerious - Use Alternative (1)prochlorperazine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)nilotinib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.norepinephrineMonitor Closely (2)prochlorperazine, norepinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only. prochlorperazine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.nortriptylineMonitor Closely (2)prochlorperazine and nortriptyline both increase QTc interval. Use Caution/Monitor. prochlorperazine and nortriptyline both increase sedation. Use Caution/Monitor.Minor (2)nortriptyline, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. nortriptyline, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.octreotideSerious - Use Alternative (1)prochlorperazine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.octreotide (Antidote)Serious - Use Alternative (1)prochlorperazine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.ofloxacinMonitor Closely (1)prochlorperazine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.olanzapineMonitor Closely (3)olanzapine and prochlorperazine both decrease QTc interval. Use Caution/Monitor. olanzapine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. olanzapine and prochlorperazine both increase sedation. Use Caution/Monitor.oliceridineMonitor Closely (1)oliceridine, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation. Increased risk of hypotension if ability to maintain blood pressure has been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (eg, phenothiazines or general anesthetics).olopatadine intranasalSerious - Use Alternative (1)prochlorperazine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. onabotulinumtoxinAMonitor Closely (3)onabotulinumtoxinA decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. onabotulinumtoxinA decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of onabotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.opium tinctureMonitor Closely (1)opium tincture and prochlorperazine both increase sedation. Use Caution/Monitor.orphenadrineMonitor Closely (1)orphenadrine and prochlorperazine both increase sedation. Use Caution/Monitor.oxaliplatinMonitor Closely (1)oxaliplatin and prochlorperazine both decrease QTc interval. Use Caution/Monitor.oxazepamMonitor Closely (1)oxazepam and prochlorperazine both increase sedation. Use Caution/Monitor.oxybutyninMonitor Closely (3)oxybutynin decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of oxybutynin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)oxybutynin increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin topicalMonitor Closely (3)oxybutynin topical decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)oxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.oxybutynin transdermalMonitor Closely (3)oxybutynin transdermal decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin transdermal decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of oxybutynin transdermal by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)oxybutynin transdermal increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.oxycodoneMonitor Closely (1)oxycodone and prochlorperazine both increase sedation. Use Caution/Monitor.oxymorphoneMonitor Closely (1)oxymorphone and prochlorperazine both increase sedation. Use Caution/Monitor.paliperidoneMonitor Closely (3)prochlorperazine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely. paliperidone and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. paliperidone and prochlorperazine both increase sedation. Use Caution/Monitor.pancuroniumMonitor Closely (3)pancuronium decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. pancuronium decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor. prochlorperazine increases effects of pancuronium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.papaveretumMonitor Closely (1)papaveretum and prochlorperazine both increase sedation. Use Caution/Monitor.papaverineMonitor Closely (1)prochlorperazine and papaverine both increase sedation. Use Caution/Monitor.parecoxibMinor (1)parecoxib will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.paroxetineMonitor Closely (2)prochlorperazine and paroxetine both increase QTc interval. Use Caution/Monitor. paroxetine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.pazopanibMonitor Closely (1)prochlorperazine and pazopanib both increase QTc interval. Use Caution/Monitor.pentamidineContraindicated (1)prochlorperazine and pentamidine both increase QTc interval. Contraindicated.pentazocineMonitor Closely (1)pentazocine and prochlorperazine both increase sedation. Use Caution/Monitor.pentobarbitalMonitor Closely (1)pentobarbital and prochlorperazine both increase sedation. Use Caution/Monitor.perindoprilMinor (1)prochlorperazine increases effects of perindopril by unspecified interaction mechanism. Minor/Significance Unknown.perphenazineMonitor Closely (2)perphenazine and prochlorperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. perphenazine and prochlorperazine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)perphenazine and prochlorperazine both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)perphenazine will increase the level or effect of prochlorperazine by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.phendimetrazineMonitor Closely (2)prochlorperazine, phendimetrazine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden